427 related articles for article (PubMed ID: 14695400)
1. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings.
Huppertz A; Balzer T; Blakeborough A; Breuer J; Giovagnoni A; Heinz-Peer G; Laniado M; Manfredi RM; Mathieu DG; Mueller D; Reimer P; Robinson PJ; Strotzer M; Taupitz M; Vogl TJ;
Radiology; 2004 Jan; 230(1):266-75. PubMed ID: 14695400
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.
Bluemke DA; Sahani D; Amendola M; Balzer T; Breuer J; Brown JJ; Casalino DD; Davis PL; Francis IR; Krinsky G; Lee FT; Lu D; Paulson EK; Schwartz LH; Siegelman ES; Small WC; Weber TM; Welber A; Shamsi K
Radiology; 2005 Oct; 237(1):89-98. PubMed ID: 16126918
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
Zhang HM; Ouyang H; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
[TBL] [Abstract][Full Text] [Related]
4. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid.
Kim YK; Kwak HS; Kim CS; Han YM
J Magn Reson Imaging; 2009 Aug; 30(2):437-43. PubMed ID: 19629973
[TBL] [Abstract][Full Text] [Related]
5. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
[TBL] [Abstract][Full Text] [Related]
6. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization.
Kubaska S; Sahani DV; Saini S; Hahn PF; Halpern E
Clin Radiol; 2001 May; 56(5):410-5. PubMed ID: 11384141
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing hemangiomas from malignant solid hepatic lesions: a comparison of heavily T2-weighted images obtained before and after administration of gadoxetic acid.
Ahn SJ; Kim MJ; Hong HS; Kim KA; Song HT
J Magn Reson Imaging; 2011 Aug; 34(2):310-7. PubMed ID: 21598345
[TBL] [Abstract][Full Text] [Related]
9. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
[TBL] [Abstract][Full Text] [Related]
11. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.
Petersein J; Spinazzi A; Giovagnoni A; Soyer P; Terrier F; Lencioni R; Bartolozzi C; Grazioli L; Chiesa A; Manfredi R; Marano P; Van Persijn Van Meerten EL; Bloem JL; Petre C; Marchal G; Greco A; McNamara MT; Heuck A; Reiser M; Laniado M; Claussen C; Daldrup HE; Rummeny E; Kirchin MA; Pirovano G; Hamm B
Radiology; 2000 Jun; 215(3):727-36. PubMed ID: 10831691
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
[TBL] [Abstract][Full Text] [Related]
13. Can a multiphasic contrast-enhanced three-dimensional fast spoiled gradient-recalled echo sequence be sufficient for liver MR imaging?
Coulam CH; Chan FP; Li KC
AJR Am J Roentgenol; 2002 Feb; 178(2):335-41. PubMed ID: 11804888
[TBL] [Abstract][Full Text] [Related]
14. Optimal T2-weighted MR cholangiopancreatographic images can be obtained after administration of gadoxetic acid.
Kim KA; Kim MJ; Park MS; Lim JS; Choi JY; Hong HS; Kim KW
Radiology; 2010 Aug; 256(2):475-84. PubMed ID: 20656837
[TBL] [Abstract][Full Text] [Related]
15. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
16. Detection and characterization of small focal hepatic lesions (≤2.5 cm in diameter): a comparison of diffusion-weighted images before and after administration of gadoxetic acid disodium at 3.0T.
Song KD; Kim YK; Lee WJ; Lee MW; Park MJ; Hwang J; Lee MH
Acta Radiol; 2012 Jun; 53(5):485-93. PubMed ID: 22535883
[TBL] [Abstract][Full Text] [Related]
17. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
[TBL] [Abstract][Full Text] [Related]
18. Assessment of fast dynamic imaging and the use of Gd-EOB-DTPA for MR-guided liver interventions.
Fischbach F; Thormann M; Seidensticker M; Kropf S; Pech M; Ricke J
J Magn Reson Imaging; 2011 Oct; 34(4):874-9. PubMed ID: 21769983
[TBL] [Abstract][Full Text] [Related]
19. Detection, classification, and characterization of focal liver lesions: Value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods.
Holzapfel K; Eiber MJ; Fingerle AA; Bruegel M; Rummeny EJ; Gaa J
Abdom Imaging; 2012 Feb; 37(1):74-82. PubMed ID: 21597893
[TBL] [Abstract][Full Text] [Related]
20. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.
Yoon JH; Lee EJ; Cha SS; Han SS; Choi SJ; Juhn JR; Kim MH; Lee YJ; Park SJ
J Vasc Interv Radiol; 2010 Mar; 21(3):348-56. PubMed ID: 20116285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
